EnglishGermanChinese (Simplified)FrenchJapanese
What's Is It? And how does it impact the early diagnosis of Parkinson's and Alzheimer's?

ParkinZheimer In Layman’s Terms

parkinzheimer page featured image
What's Is It? And how does it impact the early diagnosis of Parkinson's and Alzheimer's?
Share on facebook
Share on twitter
Share on linkedin

For the past two decades, Amprion has conducted scientific research on effective methods to early detect Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Our research has led us to a new paradigm in looking at neurodegenerative diseases as a spectrum disease. We call it—the ParkinZheimer Spectrum. This unique Parkinzheimer theory is the pillar of our scientific discovery in detecting misfolded Synuclein, a prion biomarker known to drive Parkinson’s disease, Alzheimer’s disease (up to 40% of Alzheimer’s patients), and Lewy Body Dementia (or LBD).

Recently, the U.S. FDA awarded Amprion Breakthrough Device Designation for detecting misfolded Synuclein. This distinct honor allows Amprion to accelerate diagnostic test development for Parkinson’s and Alzheimer’s commercially. How does the test work? In a nutshell, we detect the misfolded proteins (aka prions), including Abeta and Tau, as they are essential biomarkers related to Parkinson’s, Alzheimer’s, and other brain disorders.  This blog explains why the ParkinZheimer understanding is so vital in cracking the code on accurate diagnosis for ParkinZheimer–the missing piece to finding a cure for Parkinson’s and Alzheimer’s.

“Alzheimer’s and Parkinson’s are diseases on a spectrum. We call it the ParkinZheimer Spectrum.”

Why is understanding ParkinZheimer important to us?

Consider this: During the past three decades, Alzheimer’s and Parkinson’s drug development and clinical trials have failed to find a cure despite hefty spending of more than US$30 billion worldwide.

And yet, the need to find a cure for Alzheimer’s and Parkinson’s has never been greater. The number of people in the US diagnosed with Alzheimer’s and Parkinson’s is estimated at 5.8 million and 1 million.

These numbers will increase nearly threefold by 2050 without effective treatments, according to The Alzheimer’s Association and Parkinson’s Foundation (Parkinson.org).

These organizations also project that the combined cost of caring for Alzheimer’s and Parkinson’s patients in the US will rise to approximately $1.3 trillion by 2050, threatening our economy.

This short video will give you a more in-depth understanding of this global health challenge we face.

We believe the lack of successful drug development over the past three decades is mainly due to how Alzheimer’s and Parkinson’s are perceived. These are two distinct diseases, and therefore have been placed in separate silos.

To accelerate successful drug treatments, our scientists have gained significant new ground in innovative technology to diagnose Alzheimer’s and Parkinson’s by tracking the biomarkers, aka Misfolded Protein or Prions, of both diseases, leading us to the ParkinZheimer Spectrum theory.

Watch this short video to learn more about Prions and the role they play in ParkinZheimer.

Thanks to advancements in molecular biology, for the first time in history, we are empowered to detect these biomarkers that drive the ParkinZheimer Spectrum. Early and with certainty. Why this paradigm change?

“Because this new thinking gives us a new lens in looking at an old problem where advancement had been impossible.”

At Amprion, our goal is to share our new approach in analyzing and diagnosing these elusive diseases to advance drug development to find a cure.

The ParkinZheimer theory enables us to focus on these diseases based on their similarities instead of their differences.

Science has advanced, and the time has come to expand our horizons in looking at Alzheimer’s and Parkinson’s as ParkinZheimer.  Our new approach leads us to examine these diseases through their similarities instead of differences.

How to accurately detect Alzheimer’s and Parkinson’s early?

Amprion’s Prion Early Detection Science aims to gather newfound knowledge on how and when ParkinZheimer starts in the body at the earliest stages.

Chief Scientific Officer Claudio Soto discusses the science behind Amprion’s early detection testing for ParkinZheimer.

When will Amprion’s tests be ready?

Our FDA Breakthrough Device Designation for detecting Misfolded Protein Synuclein, a biomarker related to Parkinson’s and a select group of Alzheimer’s patients, is expected to launch in selective markets in the first quarter of 2021.

Want to join our Priority List for the Synuclein test?  Sign up here.

To take Alzheimer’s or Parkinson’s Awareness quizzes, click on the links below. We respect your privacy and will only use these data for Amprion’s assessment for testing priorities.

At Amprion, we strive to crack the code on brain health.  We believe that Alzheimer’s, Parkinson’s, and other neurodegenerative diseases are related and lie on the ParkinZheimer Spectrum.

Read the full article on ParkinZheimer.

If you have any questions or comments on this article, please let us know. We’d love to hear from you.

Related Articles

Scroll to Top
Share on facebook
Share on twitter
Share on linkedin
Amprion Icon
Make Every Minute Count. Join the Fight!